A Phase 2, Single-arm, Open-label, Study to Evaluate the Safety and Efficacy of MGTA-456 in Patients with Inherited Metabolic Disorders (IMD) Undergoing Hematopoietic Stem Cell (HSC) Transplantation (HSCT)
|Effective start/end date||1/15/18 → 1/14/21|
- MAGENTA THERAPEUTICS
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.